Moderna's Post-Pandemic Crisis: From Vaccine Success to Corporate Challenges
By
toomanyrichies
A baker's-dozen of insight crammed into one ring.
Summary
The article examines Moderna's current crisis despite its success with the COVID-19 vaccine. After achieving a 95% effective vaccine and massive profits during the pandemic, the company now faces significant challenges in its 15-year history. The piece explores how Moderna's ambitious expansion plans and internal issues have led to its current predicament, contrasting its earlier triumphant declaration that the vaccine success was "just the beginning" with the reality of its current struggles.
Key quotes
· 4 pulledThis is just the beginning
When Moderna CEO Stéphane Bancel addressed the J.P. Morgan Healthcare Conference in January 2021 — virtually, along with the rest of the participants who tuned in at the height of the Covid-19 pandemic — he was armed with two things he'd lacked the year before: a vaccine that was 95% effective against a virus that had shut down the world, and a slogan.
The phrase, repeated and reprinted dozens of times thereafter, tidily summed up the company's monumental ambitions: to plow the profits and know-how from its Covid coup into a new crop of mRNA vac
Exclusive: The inside story of why Moderna now faces a crisis unlike any in its 15-year-history.
You might also wanna read
Drugmakers Plan Price Increases on 350+ Medications Despite Government Pressure
Drugmakers plan to raise U.S. prices on at least 350 branded medications in 2026, including COVID, RSV, and shingles vaccines, as well as ca
reuters.com·5mo ago
Pfizer's Early 1990s Decision to Abandon Promising GLP-1 Therapy Development
The article reveals previously untold history about early GLP-1 drug development in the late 1980s and early 1990s. The author was part of w
statnews.com·5mo ago
Prescription Drug Miebo Costs $800 in U.S. vs. $20 Over-the-Counter in Europe
The article reveals stark differences in drug pricing and accessibility between the U.S. and Europe, using Miebo (EvoTears) as a case study.
statnews.com·5mo ago
FDA Drug Regulator Accused of Targeting Former Business Associate's Pharmaceutical Company
The article discusses a scandal at the FDA involving a top drug regulator who allegedly used his position to target a former business associ
arstechnica.com·6mo ago
Amgen's PCSK9 Patent Battle: Legal Loss but Commercial Victory
This article examines Amgen's legal battle over PCSK9 cholesterol drugs, specifically their patent dispute with Sanofi and Regeneron. Amgen
alexkesin.com·8mo ago
Tech Companies Stock Offices with Nicotine Products to Boost Employee Productivity
Tech companies like Palantir and Hello Patient are stocking office vending machines with nicotine products (pouches from startups Lucy and S
fortune.com·13h ago